Clinical trial
Cladribine in Patients With Mantle Cell Lymphoma
NCT00002879 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00002879 |
|---|---|
| Title | Cladribine in Patients With Mantle Cell Lymphoma |
| Official title | A PHASE II TRIAL OF 2-CDA IN PREVIOUSLY TREATED OR UNTREATED PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | cladribine |
| Enrollment | 51 |
| Start date | Nov 1, 1996 |
| Primary completion | Apr 1, 2005 |
| Completion | Dec 1, 2008 |
| First posted | Aug 24, 2004 |
| Last update posted | Dec 7, 2016 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: